SEC 13F Intelligence

Managers / Q1 2025 · view latest →

Privium Fund Management B.V.

CIK 0001795097 · GUSTAV MAHLERPLEIN 3, AMSTERDAM, P7, 1082 MS · 31 20 462 6644

Reported Value
$384M
Q1 2025
Positions
56
Filings on Record
20
2019–present window
Filed
May 9, 2025
original filing

Summary

Privium Fund Management B.V. reported $384M in U.S.-listed holdings across 56 positions for Q1 2025.

The portfolio is heavily concentrated: Spotify Technology S A alone accounts for 21.0% of reported value.

Compared with Q4 2024, the fund opened 5 new positions and exited 13.

Portfolio Metrics

Turnover
+10.1%
vs prior filed quarter
Top-10 Concentration
+77.1%
share of reported value
Largest Position
+21.0%
Spotify Technology S A
New / Exited
5 / 13
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’21: $504MQ4 ’21Q1 ’22: $452MQ2 ’22: $302MQ3 ’22: $275MQ3 ’22Q4 ’22: $264MQ1 ’23: $298MQ2 ’23: $347MQ2 ’23Q3 ’23: $336MQ4 ’23: $359MQ1 ’24: $374MQ1 ’24Q2 ’24: $392MQ3 ’24: $402MQ4 ’24: $442MQ4 ’24Q1 ’25: $384MQ2 ’25: $464MQ3 ’25: $556MQ3 ’25Q4 ’25: $543MQ1 ’26: $480Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 64.6%Other: 26.2%ADR: 9.0%ETP: 0.1%
  • Common Stock · 64.6% · $248M
  • Other · 26.2% · $101M
  • ADR · 9.0% · $35M
  • ETP · 0.1% · $392,978

Quarter-over-Quarter Changes full breakdown →

vs Q4 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SWTXUSDSPRINGWORKS THERAPEUTICS INCNEW+124.0K124.0K+$5M$5M
VRTXVERTEX PHARMACEUTICALS INCNEW+8.3K8.3K+$4M$4M
ALNYALNYLAM PHARMACEUTICALS INCNEW+5.7K5.7K+$2M$2M
IMVTIMMUNOVANT INCNEW+72.0K72.0K+$1M$1M
VYGRVOYAGER THERAPEUTICS INCNEW+21.6K21.6K+$73,160$73,160
UROGEN PHARMA LTDADDED+79.9K107.6K+$895,390$1M
NTLAINTELLIA THERAPEUTICS INCADDED+31.0K58.7K+$94,334$417,421
ITCIEURINTRA-CELLULAR THERAPIES INCSOLD OUT−97.2K0−$8M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2025

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1SPOTIFY TECHNOLOGY S ASHS20.98%$81M145.0K
2TSLATESLA INChistory →COM14.96%$57M220.0K
3SHOPSHOPIFY INChistory →CL A10.38%$40M415.0K
4PLTRPALANTIR TECHNOLOGIES INChistory →CL A7.98%$31M360.0K
5SESEA LTDhistory →SPONSORD ADS7.15%$27M210.0K
6AMZNAMAZON COM INChistory →COM7.03%$27M141.0K
7RAREULTRAGENYX PHARMACEUTICAL INhistory →COM2.36%$9M249.8K
8ISIIONIS PHARMACEUTICALS INChistory →COM2.10%$8M267.6K
9ARWRARROWHEAD PHARMACEUTICALS INhistory →COM2.09%$8M629.2K
10NVDANVIDIA CORPORATIONhistory →COM2.07%$8M73.0K
11SNOWSNOWFLAKE INChistory →CL A1.86%$7M48.0K
12NETCLOUDFLARE INChistory →CL A COM1.76%$7M60.0K
13PROQR THRAPEUTICS N VSHS EURO1.73%$7M4.99M
14AXSMAXSOME THERAPEUTICS INChistory →COM1.60%$6M52.7K
15UNIQURE NVSHS1.60%$6M579.1K
16SWTXUSDSPRINGWORKS THERAPEUTICS INChistory →COM1.43%$5M124.0K
17ARQTARCUTIS BIOTHERAPEUTICS INChistory →COM1.33%$5M325.7K
18ZLABZAI LAB LTDhistory →ADR1.25%$5M132.2K
19VRTXVERTEX PHARMACEUTICALS INChistory →COM1.05%$4M8.3K
20MRKMERCK & CO INCCOM0.96%$4M41.1K
21RCKTROCKET PHARMACEUTICALS INCCOM0.75%$3M432.8K
22ACADACADIA PHARMACEUTICALS INCCOM0.64%$2M148.4K
23MRNAMODERNA INCCOM0.56%$2M75.6K
24CRISPR THERAPEUTICS AGNAMEN AKT0.53%$2M60.1K
25ABEVAMBEV SASPONSORED ADR0.49%$2M804.2K
26CPNGCOUPANG INCCL A0.48%$2M81.9K
27ALNYALNYLAM PHARMACEUTICALS INCCOM0.40%$2M5.7K
28KRYSKRYSTAL BIOTECH INCCOM0.35%$1M7.5K
29ROIVANT SCIENCES LTDSHS0.33%$1M126.9K
30IMVTIMMUNOVANT INCCOM0.32%$1M72.0K
31UROGEN PHARMA LTDCOM0.31%$1M107.6K
32RNAGBPAVIDITY BIOSCIENCES INCCOM0.27%$1M34.5K
33WAVE LIFE SCIENCES LTDSHS0.24%$917,484113.5K
34PFEPFIZER INCCOM0.21%$819,16732.3K
35VALARIS LTDCL A0.21%$793,91620.2K
36MEIRAGTX HLDGS PLCCOM0.21%$793,260117.0K
37NOVNOV INCCOM0.20%$757,11949.7K
38RXRXRECURSION PHARMACEUTICALS INCL A0.16%$629,510119.0K
39AIGAMERICAN INTL GROUP INCCOM NEW0.15%$563,6326.5K
40LXEOLEXEO THERAPEUTICS INCCOM0.14%$555,887160.2K
41PAASPAN AMERN SILVER CORPCOM0.14%$549,76621.3K
42SEA1EURSEABRIDGE GOLD INCCOM0.13%$514,34444.1K
43EMXEMX RTY CORPCOM0.12%$442,615217.0K
44VZLAVIZSLA SILVER CORPCOM NEW0.11%$436,945192.5K
45FDMT4D MOLECULAR THERAPEUTICS INCOM0.11%$423,130131.0K
46NTLAINTELLIA THERAPEUTICS INCCOM0.11%$417,42158.7K
47SPROTT FDS TRURANIUM MINERS E0.10%$392,97812.1K
48AUTLAUTOLUS THERAPEUTICS PLCSPON ADS0.10%$390,094251.7K
49NOBLE CORP PLCORD SHS A0.09%$338,60214.3K
50ALXOALX ONCOLOGY HLDGS INCCOM0.08%$317,144509.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$480M60May 5, 202613F-HRchanges · EDGAR ↗
Q4 2025$543M57Feb 3, 202613F-HRchanges · EDGAR ↗
Q3 2025$556M59Nov 4, 202513F-HRchanges · EDGAR ↗
Q2 2025$464M55Jul 30, 202513F-HRchanges · EDGAR ↗
Q1 2025$384M56May 9, 202513F-HRchanges · EDGAR ↗
Q4 2024$442M64Feb 11, 202513F-HRchanges · EDGAR ↗
Q3 2024$402M82Nov 1, 202413F-HRchanges · EDGAR ↗
Q2 2024$392M129Aug 1, 202413F-HRchanges · EDGAR ↗
Q1 2024$374M117Apr 30, 202413F-HRchanges · EDGAR ↗
Q4 2023$359M114Feb 26, 2024RESTATEMENTchanges · EDGAR ↗
Q3 2023$336M115Nov 6, 202313F-HRchanges · EDGAR ↗
Q2 2023$347M124Jul 26, 2023RESTATEMENTchanges · EDGAR ↗
Q1 2023$298M126May 3, 202313F-HRchanges · EDGAR ↗
Q4 2022$264M150Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$275M226Nov 3, 202213F-HRchanges · EDGAR ↗
Q2 2022$302M252Jul 28, 202213F-HRchanges · EDGAR ↗
Q1 2022$452M279May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$504M253Feb 9, 202213F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.